AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Exelixis Presents at 2025 Wells Fargo Healthcare Conference: Key Takeaways and Insights
ByAinvest
Wednesday, Sep 3, 2025 3:48 pm ET1min read
Exelixis, a commercial-stage biotech company, is presenting at the 2025 Wells Fargo Healthcare Conference. The company's CEO, Michael Morrissey, will discuss the state of the business, including its focus on oncology and its lead drug, cabozantinib, which is used to treat kidney cancer. Morrissey will also address potential risks and forward-looking statements.
Exelixis, Inc. (NASDAQ: EXEL) has announced the appointment of Dana T. Aftab, Ph.D., as its Executive Vice President, Research and Development. Dr. Aftab, who has been with the company for over 25 years, will oversee all aspects of Exelixis' drug discovery, translational research, product development, and medical affairs activities [1].Dr. Aftab has a deep expertise that spans the drug discovery and development continuum. He has been a key contributor to many of Exelixis' most important milestones, including the discovery, development, and introduction of cabozantinib, which he and the broader Exelixis team grew from an initial orphan drug indication into a global oncology franchise [1].
In his new role, Dr. Aftab will lead Exelixis' wide-ranging product development organization as the team maximizes the opportunities for its portfolio. This includes cabozantinib, zanzalintinib, a third-generation oral tyrosine kinase inhibitor currently in multiple pivotal trials, and an earlier stage pipeline of promising small molecules and biotherapeutics [1].
Exelixis' CEO, Michael M. Morrissey, Ph.D., said, "Dana is an excellent choice to lead our product development organization as we continue to maximize the opportunities for our portfolio" [1].
The appointment comes as Exelixis prepares to present at the 2025 Wells Fargo Healthcare Conference, where CEO Morrissey will discuss the state of the business, its focus on oncology, and its lead drug, cabozantinib, which is used to treat kidney cancer. Morrissey will also address potential risks and forward-looking statements [1].
References:
[1] https://www.marketscreener.com/news/exelixis-announces-appointment-of-dana-t-aftab-ph-d-as-executive-vice-president-research-and-dev-ce7c50d2d18df323
[2] https://finance.yahoo.com/news/exelixis-inc-exel-halts-phase-085127677.html
[3] https://www.morningstar.com/news/business-wire/20250829389096/exelixis-announces-appointment-of-dana-t-aftab-phd-as-executive-vice-president-research-and-development
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet